Sovran Advisors LLC Buys New Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Sovran Advisors LLC purchased a new position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 113,457 shares of the biopharmaceutical company’s stock, valued at approximately $2,867,000. Sovran Advisors LLC owned approximately 0.17% of Celldex Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently added to or reduced their stakes in CLDX. KBC Group NV boosted its stake in Celldex Therapeutics by 31.2% during the 3rd quarter. KBC Group NV now owns 2,081 shares of the biopharmaceutical company’s stock valued at $71,000 after purchasing an additional 495 shares during the last quarter. AQR Capital Management LLC grew its holdings in Celldex Therapeutics by 23.7% during the second quarter. AQR Capital Management LLC now owns 7,857 shares of the biopharmaceutical company’s stock worth $291,000 after buying an additional 1,504 shares in the last quarter. Handelsbanken Fonder AB raised its position in Celldex Therapeutics by 23.2% in the 3rd quarter. Handelsbanken Fonder AB now owns 13,800 shares of the biopharmaceutical company’s stock valued at $469,000 after buying an additional 2,600 shares during the last quarter. Point72 DIFC Ltd lifted its stake in Celldex Therapeutics by 101.7% during the 3rd quarter. Point72 DIFC Ltd now owns 14,114 shares of the biopharmaceutical company’s stock valued at $480,000 after acquiring an additional 7,116 shares in the last quarter. Finally, Creative Planning bought a new stake in shares of Celldex Therapeutics in the 3rd quarter worth $504,000.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the stock. HC Wainwright reissued a “buy” rating and set a $80.00 price target on shares of Celldex Therapeutics in a research report on Thursday, December 19th. Cantor Fitzgerald restated an “overweight” rating and issued a $67.00 target price on shares of Celldex Therapeutics in a research note on Wednesday, January 29th. Two analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Celldex Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $62.25.

Celldex Therapeutics Stock Down 4.2 %

NASDAQ:CLDX opened at $21.53 on Tuesday. Celldex Therapeutics, Inc. has a 12 month low of $21.18 and a 12 month high of $53.18. The firm’s 50 day moving average is $25.13 and its 200 day moving average is $30.40.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.